Lantheus, a company in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, completed the acquisition of Cerveau Technologies,a provider of information and technologies to researchers and clinicians to improve brain health. Financial terms were not disclosed. “This exciting acquisition aligns with our growth strategy, further diversifying our radiopharmaceutical diagnostic imaging agent pipeline to now include the most widely-used Tau PET imaging agent in Alzheimer’s disease and will provide us with an extensive roster of academic collaborations and pharmaceutical partnerships,” Etienne Montagut, Lantheus Chief Business Officer.